Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
06 March 2024 - 12:00AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today that members of management will participate in the
following upcoming investor conferences:
-
Leerink Global Biopharma Conference: Fireside chat on Monday, March
11 at 3:20 p.m. ET.
- UBS Virtual CNS Day:
Fireside chat on Monday, March 18 at 12:30 p.m. ET.
A live webcast of these events, as well as an
archived recordings, will be available on Avadel’s Investor
Relations website, investors.avadel.com, for 90 days following each
conference.
About Avadel Pharmaceuticals
plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a
biopharmaceutical company focused on transforming medicines to
transform lives. Our approach includes applying innovative
solutions to the development of medications that address the
challenges patients face with current treatment options. Avadel’s
commercial product, LUMRYZ™, was approved by the U.S. Food
& Drug Administration (FDA) as the first and only
once-at-bedtime oxybate for the treatment of cataplexy or excessive
daytime sleepiness (EDS) in adults with narcolepsy. For more
information, please visit www.avadel.com.
Investor Contact:Courtney
MogerleyStern Investor Relations, Inc.Courtney.Mogerley@sternir.com
(212) 698-8687
Media Contact:Lesley StanleyReal
Chemistrylestanley@realchemistry.com(609) 273-3162
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Apr 2023 to Apr 2024